From islet of Langerhans transplantation to the bioartificial pancreas

Article Article scientifique Revue de la littérature From islet of Langerhans transplantation to the bioartificial pancreas eng 2022-10-03 2022-10-03 author Berney Thierry 63319 author Wassmer Charles-Henri 683357 author Lebreton Fanny 859340 author Bellofatto Kevin 883688 author Oliveira Almeida Fonseca Laura Do Mar 955240 author Bignard Juliette 0009-0006-8519-0182 989751 author Hanna Reine 942542 author Peloso Andréa 0000-0002-3089-0230 878393 author Berishvili Berney Ekaterine 0000-0002-7969-1937 826237 104139 10.1016/j.lpm.2022.104139 36202182 0755-4982 https://www.sciencedirect.com/science/article/pii/S075549822200032X Type 1 diabetes is a disease resulting from autoimmune destruction of the insulin-producing beta cells in the pancreas. When type 1 diabetes develops into severe secondary complications, in particular end-stage nephropathy, or life-threatening severe hypoglycemia, the best therapeutic approach is pancreas transplantation, or more recently transplantation of the pancreatic islets of Langerhans. Islet transplantation is a cell therapy procedure, that is minimally invasive and has a low morbidity, but does not display the same rate of functional success as the more invasive pancreas transplantation because of suboptimal engraftment and survival. Another issue is that pancreas or islet transplantation (collectively known as beta cell replacement therapy) is limited by the shortage of organ donors and by the need for lifelong immunosuppression to prevent immune rejection and recurrence of autoimmunity. A bioartificial pancreas is a construct made of functional, insulin-producing tissue, embedded in an anti-inflammatory, immunomodulatory microenvironment and encapsulated in a perm-selective membrane allowing glucose sensing and insulin release, but isolating from attacks by cells of the immune system. A successful bioartificial pancreas would address the issues of engraftment, survival and rejection. Inclusion of unlimited sources of insulin-producing cells, such as xenogeneic porcine islets or stem cell-derived beta cells would further solve the problem of organ shortage. This article reviews the current status of clinical islet transplantation, the strategies aiming at developing a bioartificial pancreas, the clinical trials conducted in the field and the perspectives for further progress. Animals Diabetes Mellitus, Type 1 / surgery Insulin Islets of Langerhans Transplantation / methods Islets of Langerhans Pancreas Pancreas Transplantation / methods Swine Dewey 617 European Commission New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes 874700 VANGUARD EU H2020 Swiss National Science Foundation Toward The Bioartificial Pancreas: Bioengineering Of Novel Vascularized, Insulin-Secreting, Immunoprotective 3D Constructs On Human Amniotic Membrane Matrix 173138 CH Projects 57 Département de chirurgie 222 false 1323 Création de tissus par bio-ingénieurie et régénération d'organes 1021 357 La transplantation d'îlots de Langerhans 623 La Presse médicale f753baa5-9be6-41e7-85fc-c1a9c60a3643 Article (Published version) Public 1-s2.0-S075549822200032X-main.pdf 1250662 application/pdf CC BY-4.0 openAccess Faculté de médecine / Section de médecine clinique / Département de chirurgie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

From islet of Langerhans transplantation to the bioartificial pancreas	La Presse médicale			2022	232	476

Archive ouverte UNIGE

Lebreton, Fanny